Effect of Genetic Polymorphisms on Platinum Based Chemotherapy in Non Small Cell Lung Cancer

Ain Shams University60 enrolled

Overview

This Study evaluate the effect of Polymorphism in the Excision repair cross-complementing group 5 (ERCC5) (rs1047768 and rs751402) gene on the clinical outcome of Platinum-based regimens used in the treatment of Non-Small Cell Lung Cancer (NSCLC) patients

Study Type

OBSERVATIONAL

Enrollment

Conditions

Carcinoma, Non-Small-Cell Lung

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Newly diagnosed with immunohistochemically and pathologically confirmed non-small cell lung cancer (NSCLC). 2. Eastern Cooperative Oncology Group performance status (ECOG PS) = 0-2. 3. Chemotherapy naïve. 4. Age \>18 years. 5. Adequate bone marrow reserve Exclusion Criteria: 1. Presence of Central nervous system(CNS) metastases. 2. Inadequate liver function 3. Inadequate renal function 4. Serious comorbid systemic disorder incompatible with the study. 5. Pregnancy

Locations (1)

Al Demerdash Hospital

Cairo, Egypt

RECRUITING

Outcomes

Primary Outcomes

Progression-free survival (PFS)

It's defined as the time from day 1 of chemotherapy to the day of documented disease progression or death from any cause.

Time frame: From the date of starting the chemotherapy until the date of documented disease progression or date of death from any cause assessed up to 12 months

Central Contacts

demonstrator of clinical pharmacy

CONTACT

01151958437 esraa.salah@pharm.asu.edu.eg

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.